Gossamer Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors surrounding Gossamer Bio’s promising developments in their clinical programs. The company is advancing seralutinib, an inhaled tyrosine kinase inhibitor, which is positioned to be a best-in-class treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD). With the Phase 3 PROSERA trial fully enrolled and results expected in February 2026, alongside the upcoming SERANATA trial, Gossamer is on the cusp of delivering significant clinical milestones.
Moreover, seralutinib’s unique mechanism, which targets vascular remodeling rather than traditional vasodilation, sets it apart from existing therapies and could lead to a meaningful treatment effect. The strategic partnership with Chiesi and a strong cash position of $212.9 million are also seen as critical factors supporting a successful commercial launch if seralutinib is approved. These developments, coupled with the potential for seralutinib to become a blockbuster drug, underpin Trucchio’s Buy rating and the $10 price target for Gossamer Bio’s stock.
In another report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $6.00 price target.